This article offers a patient perspective on the recent FDA approval of Cobenfy, the first new antipsychotic drug in decades. While acknowledging the drug's potential to reduce debilitating side effects like weight gain and movement disorders, the author expresses hesitation to try it due to a deep-seated lack of trust in the mental health care system and pharmaceutical companies. The piece highlights that medication non-adherence is often driven by systemic trauma and mistrust, not just side effects.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.